{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:32:13Z","timestamp":1787585533655,"version":"build-2736575974"},"reference-count":154,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404003"],"award-info":[{"award-number":["82404003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["82404003"],"award-info":[{"award-number":["82404003"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Post-Doctor Research Project, West China Hospital, Sichuan University","award":["2024HXBH147"],"award-info":[{"award-number":["2024HXBH147"]}]},{"award":["2024HXBH147"],"award-info":[{"award-number":["2024HXBH147"]}],"id":[{"id":"https:\/\/ror.org\/011ashp19","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Alternative pre-mRNA splicing is a central layer of gene regulation that enables a limited number of genes to generate a far larger and more context-dependent transcriptome and proteome. In cancer, splicing is disrupted by mutations in cis-regulatory sequences, recurrent lesions in spliceosome components, altered abundance or activity of RNA-binding proteins, and changes in transcription, chromatin, RNA modification, metabolism and stress signalling. These alterations are not merely by-products of malignant transformation. They can create oncogenic protein isoforms, eliminate tumour-suppressive products, remodel cellular identity, promote metastasis and drug resistance, and generate tumour-restricted peptides that are visible to the immune system. Large pan-cancer datasets, long-read sequencing, single-cell isoform profiling, proteogenomics and functional perturbation screens are now resolving this complexity at unprecedented scale. In parallel, multiple therapeutic strategies are advancing, including modulators of the SF3B complex, molecular glues that degrade RBM39, inhibitors of protein arginine methyltransferases and splicing kinases, splice-switching oligonucleotides, programmable RNA-targeting systems, and vaccines or T-cell receptors directed against splicing-derived neoantigens. This review integrates the molecular logic of splice-site selection with the cancer-specific mechanisms that perturb it, summarizes representative isoform switches across the hallmarks of cancer, evaluates emerging technologies and clinical biomarkers, and discusses the opportunities and constraints of translating splicing biology into precision oncology. Particular emphasis is placed on tumour specificity, intratumoural heterogeneity, proteomic validation, therapeutic windows and rational combination strategies.<\/jats:p>","DOI":"10.3390\/genes17090984","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:49:34Z","timestamp":1787582974000},"page":"984","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alternative RNA Splicing in Cancer: Molecular Mechanisms, Functional Consequences, Biomarkers and Therapeutic Opportunities"],"prefix":"10.3390","volume":"17","author":[{"given":"Quanyou","family":"Wu","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Targeted Therapy in Oncology, Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Gui","sequence":"additional","affiliation":[{"name":"Key Laboratory of Clinical Laboratory Diagnostics, Ministry of Education, School of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-biochem-060614-034316","article-title":"Mechanisms and regulation of alternative pre-mRNA splicing","volume":"84","author":"Lee","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.cell.2009.02.009","article-title":"The spliceosome: Design principles of a dynamic RNP machine","volume":"136","author":"Wahl","year":"2009","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"a032409","DOI":"10.1101\/cshperspect.a032409","article-title":"Molecular mechanisms of pre-mRNA splicing through structural biology of the spliceosome","volume":"11","author":"Yan","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41576-022-00556-8","article-title":"Regulation of pre-mRNA splicing: Roles in physiology and disease, and therapeutic prospects","volume":"24","author":"Rogalska","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.molcel.2019.09.017","article-title":"Alternative splicing regulatory networks: Functions, mechanisms, and evolution","volume":"76","author":"Ule","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/wrna.1260","article-title":"The RNAissance family: SR proteins as multifaceted regulators of gene expression","volume":"6","author":"Howard","year":"2015","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41576-022-00514-4","article-title":"Alternative splicing as a source of phenotypic diversity","volume":"23","author":"Wright","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e1707","DOI":"10.1002\/wrna.1707","article-title":"Uncovering the impacts of alternative splicing on the proteome with current omics techniques","volume":"13","author":"Eyras","year":"2022","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","article-title":"RNA splicing dysregulation and the hallmarks of cancer","volume":"23","author":"Bradley","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41571-020-0350-x","article-title":"Roles and mechanisms of alternative splicing in cancer\u2014Implications for care","volume":"17","author":"Bonnal","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s43018-022-00384-z","article-title":"Dysregulation and therapeutic targeting of RNA splicing in cancer","volume":"3","author":"Stanley","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.trecan.2020.04.011","article-title":"RNA splicing and cancer","volume":"6","author":"Wang","year":"2020","journal-title":"Trends Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-021-00486-7","article-title":"Alternative splicing and cancer: A systematic review","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1101\/gad.338962.120","article-title":"Alternative splicing and cancer: Insights, opportunities, and challenges from an expanding view of the transcriptome","volume":"34","author":"Cherry","year":"2020","journal-title":"Genes Dev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s41568-024-00750-2","article-title":"Steering research on mRNA splicing in cancer towards clinical translation","volume":"24","author":"Anczukow","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-024-01734-2","article-title":"Alternative splicing and related RNA binding proteins in human health and disease","volume":"9","author":"Tao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.celrep.2018.01.088","article-title":"Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types","volume":"23","author":"Buonamici","year":"2018","journal-title":"Cell Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-019-1651-z","article-title":"The U1 spliceosomal RNA is recurrently mutated in multiple cancers","volume":"574","author":"Shuai","year":"2019","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/blood.2019004260","article-title":"Splicing factor mutations in hematologic malignancies","volume":"138","author":"Chen","year":"2021","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.celrep.2015.09.053","article-title":"Cancer-associated SF3B1 hotspot mutations induce cryptic 3\u2032 splice site selection through use of a different branch point","volume":"13","author":"Darman","year":"2015","journal-title":"Cell Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10615","DOI":"10.1038\/ncomms10615","article-title":"Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage","volume":"7","author":"Alsafadi","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-020-00220-5","article-title":"The biological function and clinical significance of SF3B1 mutations in cancer","volume":"8","author":"Zhou","year":"2020","journal-title":"Biomark. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1016\/j.molcel.2024.07.019","article-title":"Molecular impact of mutations in RNA splicing factors in cancer","volume":"84","author":"Zhang","year":"2024","journal-title":"Mol. Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1038\/s41467-020-18559-6","article-title":"Elucidation of the aberrant 3\u2032 splice site selection by cancer-associated mutations on U2AF1","volume":"11","author":"Yoshida","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"14060","DOI":"10.1038\/ncomms14060","article-title":"Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome","volume":"8","author":"Shirai","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","article-title":"Comprehensive analysis of alternative splicing across tumors from 8,705 patients","volume":"34","author":"Kahles","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"114893","DOI":"10.1016\/j.celrep.2024.114893","article-title":"RNA splicing junction landscape reveals abundant tumor-specific transcripts in human cancer","volume":"43","author":"Li","year":"2024","journal-title":"Cell Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7039","DOI":"10.1038\/s41467-024-51380-z","article-title":"In silico RNA isoform screening to identify potential cancer driver exons with therapeutic applications","volume":"15","author":"Ciampi","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.celrep.2018.03.052","article-title":"Systematic analysis of splice-site-creating mutations in cancer","volume":"23","author":"Jayasinghe","year":"2018","journal-title":"Cell Rep."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"De Paoli-Iseppi, R., Gleeson, J., and Clark, M.B. (2021). Isoform age\u2014Splice isoform profiling using long-read technologies. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.711733"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/j.csbj.2023.03.023","article-title":"Single-cell and long-read sequencing to enhance modelling of splicing and cell-fate determination","volume":"21","author":"Wu","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101255","DOI":"10.1016\/j.mam.2024.101255","article-title":"Single-cell and spatial transcriptomics: Bridging current technologies with long-read sequencing","volume":"96","author":"Yuan","year":"2024","journal-title":"Mol. Asp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6654","DOI":"10.1038\/s41467-025-60902-2","article-title":"Single cell and spatial alternative splicing analysis with Nanopore long read sequencing","volume":"16","author":"Fu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/procel\/pwaf049","article-title":"Systematic characterization of full-length RNA isoforms in human colorectal cancer at single-cell resolution","volume":"16","author":"Lu","year":"2025","journal-title":"Protein Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"eade2886","DOI":"10.1126\/scitranslmed.ade2886","article-title":"Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy","volume":"16","author":"Li","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41592-024-02298-3","article-title":"Systematic assessment of long-read RNA-seq methods for transcript identification and quantification","volume":"21","author":"Wang","year":"2024","journal-title":"Nat. Methods"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1038\/s41467-026-72258-2","article-title":"Mapping glioblastoma\u2019s isoform diversity using long-read single-cell analysis","volume":"17","author":"Tang","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nbt.4239","article-title":"Intron retention is a source of neoepitopes in cancer","volume":"36","author":"Smart","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"eaau5516","DOI":"10.1126\/scitranslmed.aau5516","article-title":"Noncoding regions are the main source of targetable tumor-specific antigens","volume":"10","author":"Laumont","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-024-08552-0","article-title":"Tumour-wide RNA splicing aberrations generate actionable public neoantigens","volume":"639","author":"Kwok","year":"2025","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.cell.2025.03.047","article-title":"Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias","volume":"188","author":"Kim","year":"2025","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1101\/gad.219899.113","article-title":"Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery","volume":"27","author":"Bezzi","year":"2013","journal-title":"Genes Dev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0092-8674(93)90508-N","article-title":"bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death","volume":"74","author":"Boise","year":"1993","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"25255","DOI":"10.1074\/jbc.M909826199","article-title":"MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain","volume":"275","author":"Bae","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00439-016-1683-5","article-title":"The hnRNP family: Insights into their role in health and disease","volume":"135","author":"Geuens","year":"2016","journal-title":"Hum. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1016\/j.apsb.2023.05.022","article-title":"Towards understandings of serine\/arginine-rich splicing factors","volume":"13","author":"Li","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.tig.2023.04.008","article-title":"Pre-mRNA splicing and its cotranscriptional connections","volume":"39","author":"Shenasa","year":"2023","journal-title":"Trends Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1184208","article-title":"Regulation of alternative splicing by histone modifications","volume":"327","author":"Luco","year":"2010","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.celrep.2015.03.048","article-title":"SF3B1 association with chromatin determines splicing outcomes","volume":"11","author":"Kfir","year":"2015","journal-title":"Cell Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e1815","DOI":"10.1002\/wrna.1815","article-title":"Regulation of alternative splicing: Functional interplay with epigenetic modifications and its implication to cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.molcel.2016.01.012","article-title":"Nuclear m6A reader YTHDC1 regulates mRNA splicing","volume":"61","author":"Xiao","year":"2016","journal-title":"Mol. Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cell.2015.08.011","article-title":"HNRNPA2B1 is a mediator of m6A-dependent nuclear RNA processing events","volume":"162","author":"Goodarzi","year":"2015","journal-title":"Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nature14234","article-title":"N6-methyladenosine-dependent RNA structural switches regulate RNA\u2013protein interactions","volume":"518","author":"Liu","year":"2015","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.cell.2017.05.045","article-title":"Dynamic RNA modifications in gene expression regulation","volume":"169","author":"Roundtree","year":"2017","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"442","DOI":"10.15252\/emmm.201506055","article-title":"The dark matter of the cancer genome: Aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations","volume":"8","author":"Diederichs","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/onc.2015.318","article-title":"Aberrant RNA splicing in cancer: Expression changes and driver mutations of splicing factor genes","volume":"35","author":"Sveen","year":"2016","journal-title":"Oncogene"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1541-7786.MCR-19-0415","article-title":"A novel FGFR3 splice variant preferentially expressed in African American prostate cancer drives aggressive phenotypes and docetaxel resistance","volume":"17","author":"Olender","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1158\/1535-7163.MCT-14-1057","article-title":"NF-\u03baB2\/p52:c-Myc:hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer","volume":"14","author":"Nadiminty","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e202301955","DOI":"10.26508\/lsa.202301955","article-title":"SF3B1 mutation-mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia","volume":"6","author":"Gohr","year":"2023","journal-title":"Life Sci. Alliance"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/nm.4097","article-title":"Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins","volume":"22","author":"Lee","year":"2016","journal-title":"Nat. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nsmb1209","article-title":"The gene encoding the splicing factor SF2\/ASF is a proto-oncogene","volume":"14","author":"Karni","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nsmb.2207","article-title":"The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation","volume":"19","author":"Rosenberg","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1158\/2159-8290.CD-22-1013","article-title":"Splicing factor SRSF1 promotes pancreatitis and KRASG12D-mediated pancreatic cancer","volume":"13","author":"Wan","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1172\/JCI120279","article-title":"Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B","volume":"129","author":"Zhou","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13046-021-01978-8","article-title":"Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1","volume":"40","author":"Du","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature14985","article-title":"The spliceosome is a therapeutic vulnerability in MYC-driven cancer","volume":"525","author":"Hsu","year":"2015","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e2220190120","DOI":"10.1073\/pnas.2220190120","article-title":"The RNA-binding proteins hnRNP H and F regulate splicing of a MYC-dependent HRAS exon in prostate cancer cells","volume":"120","author":"Chen","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"106804","DOI":"10.1016\/j.isci.2023.106804","article-title":"Hypoxia-induced loss of SRSF2-dependent DNA methylation promotes CTCF-mediated alternative splicing of VEGFA in breast cancer","volume":"26","author":"Yadav","year":"2023","journal-title":"iScience"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/0008-5472.CAN-20-2876","article-title":"Hypoxia-Induced Suppression of Alternative Splicing of MBD2 Promotes Breast Cancer Metastasis via Activation of FZD1","volume":"81","author":"Liu","year":"2021","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41388-022-02539-9","article-title":"TARDBP promotes ovarian cancer progression by altering vascular endothelial growth factor splicing","volume":"42","author":"He","year":"2023","journal-title":"Oncogene"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41419-021-03858-7","article-title":"Long noncoding RNA DGCR5 involves in tumorigenesis of esophageal squamous cell carcinoma via SRSF1-mediated alternative splicing of Mcl-1","volume":"12","author":"Duan","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12943-020-01299-y","article-title":"LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/s41388-023-02657-y","article-title":"LncRNA CACClnc promotes chemoresistance of colorectal cancer by modulating alternative splicing of RAD51","volume":"42","author":"Zhang","year":"2023","journal-title":"Oncogene"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"102493","DOI":"10.1016\/j.redox.2022.102493","article-title":"CircRAPGEF5 interacts with RBFOX2 to confer ferroptosis resistance by modulating alternative splicing of TFRC in endometrial cancer","volume":"57","author":"Zhang","year":"2022","journal-title":"Redox Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nature08697","article-title":"HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer","volume":"463","author":"David","year":"2010","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ccell.2019.07.003","article-title":"Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation","volume":"36","author":"Fong","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ccell.2019.05.014","article-title":"Anti-tumor activity of the type I PRMT inhibitor GSK3368715 synergizes with PRMT5 inhibition through MTAP loss","volume":"36","author":"Fedoriw","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/s41467-021-21204-5","article-title":"PRMT5 inhibition disrupts splicing and stemness in glioblastoma","volume":"12","author":"Sachamitr","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-21-0620","article-title":"SAM-competitive PRMT5 inhibitor PF-06939999 demonstrates antitumor activity in splicing-dysregulated NSCLC with decreased liability of drug resistance","volume":"21","author":"Tatlock","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/acs.jmedchem.1c01900","article-title":"Fragment-based discovery of MRTX1719, a synthetic lethal inhibitor of the PRMT5\u2013MTA complex for the treatment of MTAP-deleted cancers","volume":"65","author":"Smith","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1158\/1535-7163.MCT-21-0367","article-title":"Discovery and pharmacological characterization of JNJ-64619178, a novel small-molecule inhibitor of PRMT5 with potent antitumor activity","volume":"20","author":"Brehmer","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-23-0092","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in advanced solid tumors","volume":"29","author":"Vieito","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"106634","DOI":"10.1016\/j.oraloncology.2023.106634","article-title":"PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study","volume":"149","author":"Ferrarotto","year":"2024","journal-title":"Oral Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41416-023-02276-0","article-title":"Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors","volume":"129","author":"Clarke","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/2159-8290.CD-24-0887","article-title":"AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers","volume":"15","author":"Belmontes","year":"2025","journal-title":"Cancer Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41392-021-00495-6","article-title":"SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer","volume":"6","author":"Lv","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41419-024-06507-x","article-title":"Modification of BCLX pre-mRNA splicing has antitumor efficacy alone or in combination with radiotherapy in human glioblastoma cells","volume":"15","author":"Dou","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.7150\/thno.42010","article-title":"Skipping of exon 10 in Axl pre-mRNA regulated by PTBP1 mediates invasion and metastasis process of liver cancer cells","volume":"10","author":"Shen","year":"2020","journal-title":"Theranostics"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1038\/s41467-021-24498-7","article-title":"Targeting KRAS4A splicing through the RBM39\/DCAF15 pathway inhibits cancer stem cells","volume":"12","author":"Chen","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.7150\/thno.51360","article-title":"SAM68 promotes tumorigenesis in lung adenocarcinoma by regulating metabolic conversion via PKM alternative splicing","volume":"11","author":"Zhu","year":"2021","journal-title":"Theranostics"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41467-020-14437-3","article-title":"MTR4 drives liver tumorigenesis by promoting cancer metabolic switch through alternative splicing","volume":"11","author":"Yu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-017-0392-4","article-title":"NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase","volume":"10","author":"Gu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1038\/s41467-020-15815-7","article-title":"Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/emboj.2010.195","article-title":"An ESRP-regulated splicing programme is abrogated during the epithelial\u2013mesenchymal transition","volume":"29","author":"Warzecha","year":"2010","journal-title":"EMBO J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/mc.23477","article-title":"Splicing factor SRSF3 promotes the progression of cervical cancer through regulating DDX5","volume":"62","author":"Che","year":"2023","journal-title":"Mol. Carcinog."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1038\/s41388-017-0119-6","article-title":"SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-kappaB-CD47 axis","volume":"37","author":"Liu","year":"2018","journal-title":"Oncogene"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Li, Z., Qin, C., Zhao, B., Wang, Y., Li, T., Zhao, Y., and Wang, W. (2023). DHX38 restricts chemoresistance by regulating the alternative pre-mRNA splicing of RELL2 in pancreatic ductal adenocarcinoma. PLoS Genet., 19.","DOI":"10.1371\/journal.pgen.1010847"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"eadj4009","DOI":"10.1126\/sciadv.adj4009","article-title":"SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1","volume":"10","author":"Deng","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"113307","DOI":"10.1016\/j.celrep.2023.113307","article-title":"Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma","volume":"42","author":"Xu","year":"2023","journal-title":"Cell Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1038\/s41467-022-31818-y","article-title":"High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance","volume":"13","author":"Schulz","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Yan, L., Sun, Y., Guo, J., and Jia, R. (2023). PD-L1 exon 3 is a hidden switch of its expression and function in oral cancer cells. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098193"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1158\/2326-6066.CIR-20-0800","article-title":"Alternative splicing of the inhibitory immune checkpoint receptor SLAMF6 generates a dominant positive form, boosting T-cell effector functions","volume":"9","author":"Hajaj","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/2159-8290.CD-23-0282","article-title":"An inflammatory checkpoint generated by IL1RN splicing offers therapeutic opportunity for KRAS-mutant intrahepatic cholangiocarcinoma","volume":"13","author":"Zhang","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"113388","DOI":"10.1016\/j.celrep.2023.113388","article-title":"PTIR1 acts as an isoform of DDX58 and promotes tumor immune resistance through activation of UCHL5","volume":"42","author":"Song","year":"2023","journal-title":"Cell Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/2326-6066.CIR-19-0679","article-title":"The tumor microenvironment impairs Th1 IFN\u03b3 secretion through alternative splicing modifications of Irf1 pre-mRNA","volume":"9","author":"Bernard","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1038\/s41467-026-71564-z","article-title":"Spliceosome induction is a druggable dependency of RAS-driven senescence and cancer","volume":"17","author":"Wagner","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"eaal3755","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nchembio.2363","article-title":"Selective degradation of splicing factor CAPER\u03b1 by anticancer sulfonamides","volume":"13","author":"Uehara","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1038\/s41467-023-40254-5","article-title":"Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39","volume":"14","author":"Campagne","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1111\/bph.15331","article-title":"RNA-binding motif protein 39 (RBM39): An emerging cancer target","volume":"179","author":"Xu","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.01.010","article-title":"Targeting an RNA-binding protein network in acute myeloid leukemia","volume":"35","author":"Wang","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41467-022-28907-3","article-title":"Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma","volume":"13","author":"Nijhuis","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41375-023-02050-4","article-title":"E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: A phase II clinical trial","volume":"37","author":"Bewersdorf","year":"2023","journal-title":"Leukemia"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"E5593","DOI":"10.1073\/pnas.1419161111","article-title":"rMATS: Robust and flexible detection of differential alternative splicing from replicate RNA-Seq data","volume":"111","author":"Shen","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e11752","DOI":"10.7554\/eLife.11752","article-title":"A new view of transcriptome complexity and regulation through the lens of local splicing variations","volume":"5","author":"Barrera","year":"2016","journal-title":"eLife"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41588-017-0004-9","article-title":"Annotation-free quantification of RNA splicing using LeafCutter","volume":"50","author":"Li","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13059-018-1417-1","article-title":"SUPPA2: Fast, accurate, and uncertainty-aware differential splicing analysis across multiple conditions","volume":"19","author":"Trincado","year":"2018","journal-title":"Genome Biol."},{"key":"ref_125","first-page":"e7998","article-title":"Efficient and accurate quantitative profiling of alternative splicing patterns of any complexity on a laptop","volume":"14","author":"Weatheritt","year":"2018","journal-title":"Mol. Syst. Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","article-title":"Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms","volume":"35","author":"Steensma","year":"2021","journal-title":"Leukemia"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.7164\/antibiotics.49.1204","article-title":"New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action","volume":"49","author":"Nakajima","year":"1996","journal-title":"J. Antibiot."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"180","DOI":"10.7164\/antibiotics.57.180","article-title":"Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. II. Physico-chemical properties and structure elucidation","volume":"57","author":"Sakai","year":"2004","journal-title":"J. Antibiot."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1021\/cb100248e","article-title":"Identification of SAP155 as the target of GEX1A (herboxidiene), an antitumor natural product","volume":"6","author":"Hasegawa","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/1535-7163.MCT-09-0051","article-title":"Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells","volume":"8","author":"Albert","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1101\/gad.2014311","article-title":"Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A","volume":"25","author":"Corrionero","year":"2011","journal-title":"Genes Dev."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-13-0485","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors","volume":"19","author":"Eskens","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10637-013-0046-5","article-title":"A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors","volume":"32","author":"Hong","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cell.2020.12.031","article-title":"Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer","volume":"184","author":"Bowling","year":"2021","journal-title":"Cell"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1158\/0008-5472.CAN-14-2443","article-title":"CLK2 is an oncogenic kinase and splicing regulator in breast cancer","volume":"75","author":"Yoshida","year":"2015","journal-title":"Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e8289","DOI":"10.15252\/emmm.201708289","article-title":"Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability","volume":"10","author":"Iwai","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e20191779","DOI":"10.1084\/jem.20191779","article-title":"Targeting CLK3 inhibits the progression of cholangiocarcinoma by reprogramming nucleotide metabolism","volume":"217","author":"Zhou","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2019.09.009","article-title":"The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models","volume":"473","author":"Tam","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-021-01072-8","article-title":"CLK1\/SRSF5 pathway induces aberrant exon skipping of METTL14 and cyclin L2 and promotes growth and metastasis of pancreatic cancer","volume":"14","author":"Chen","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: First global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: First global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/0008-5472.CAN-20-0948","article-title":"ASO-based PKM splice-switching therapy inhibits hepatocellular carcinoma growth","volume":"82","author":"Ma","year":"2022","journal-title":"Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41416-020-0951-2","article-title":"Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer","volume":"123","author":"Li","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","article-title":"A framework for individualized splice-switching oligonucleotide therapy","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/s41467-019-09523-0","article-title":"Specific inhibition of splicing factor activity by decoy RNA oligonucleotides","volume":"10","author":"Denichenko","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1039\/D0CS01261K","article-title":"Targeting RNA with small molecules: From fundamental principles towards the clinic","volume":"50","author":"Falese","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1038\/s41467-024-46090-5","article-title":"Specificity, synergy, and mechanisms of splice-modifying drugs","volume":"15","author":"Ishigami","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"9754","DOI":"10.1038\/s41467-025-64821-0","article-title":"Mutation of CMTR2 in Lung Adenocarcinoma Alters RNA Alternative Splicing and Reveals Therapeutic Vulnerabilities","volume":"16","author":"Nukaga","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Meng, W.-Y., Xu, M., Sun, S.-X., Sun, Z.-Y., Wang, F.-C., Lu, Y., Li, Y., Shi, J., and Xue, J.-H. SMD2 reads pseudouridines to regulate mRNA splicing and promote tumorigenesis, Mol. Cell 2026, in press.","DOI":"10.1016\/j.molcel.2026.06.033"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1016\/j.cell.2026.05.003","article-title":"Transposable element DNA and RNA: Drivers of gene expression, evolution, and disease","volume":"189","author":"Ho","year":"2026","journal-title":"Cell"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"7621","DOI":"10.1016\/j.cell.2024.11.016","article-title":"Regulation of human interferon signaling by transposon exonization","volume":"187","author":"Pasquesi","year":"2024","journal-title":"Cell"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"7603","DOI":"10.1016\/j.cell.2024.11.011","article-title":"Transposable element exonization generates a reservoir of evolving and functional protein isoforms","volume":"187","author":"Arribas","year":"2024","journal-title":"Cell"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.cell.2023.04.012","article-title":"Sites of transcription initiation drive mRNA isoform selection","volume":"186","author":"Legnini","year":"2023","journal-title":"Cell"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.cell.2019.12.011","article-title":"SnapShot: Splicing alterations in cancer","volume":"180","author":"Rahman","year":"2020","journal-title":"Cell"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/9\/984\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:59:52Z","timestamp":1787583592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/9\/984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":154,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["genes17090984"],"URL":"https:\/\/doi.org\/10.3390\/genes17090984","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]}}}